204 related articles for article (PubMed ID: 32734225)
1. Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan.
Hanna RM; Velez JC; Rastogi A; Nguyen MK; Kamgar MK; Moe K; Arman F; Hasnain H; Nobakht N; Selamet U; Kurtz I
Kidney Med; 2020; 2(1):20-28. PubMed ID: 32734225
[TBL] [Abstract][Full Text] [Related]
2. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
3. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
Estilo A; McCormick L; Rahman M
Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
[TBL] [Abstract][Full Text] [Related]
4. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
5. Comparative Safety and Effectiveness of Urea and Tolvaptan for the Management of Hyponatremia.
Scalla PA; Palma SM; Dittmar E; Zamora FJ; Trimino E
J Pharm Pract; 2024 Apr; ():8971900241247617. PubMed ID: 38652561
[No Abstract] [Full Text] [Related]
6. A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.
Hagiwara D; Matsukawa M; Tasaki J; Nakamura Y; Arima H
Endocr J; 2023 Dec; 70(12):1195-1205. PubMed ID: 37914256
[TBL] [Abstract][Full Text] [Related]
7. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian C; Lesch C; Berger K
Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
[TBL] [Abstract][Full Text] [Related]
10. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
Verbalis JG; Greenberg A; Burst V; Haymann JP; Johannsson G; Peri A; Poch E; Chiodo JA; Dave J
Am J Med; 2016 May; 129(5):537.e9-537.e23. PubMed ID: 26584969
[TBL] [Abstract][Full Text] [Related]
11. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
Arima H; Goto K; Motozawa T; Mouri M; Watanabe R; Hirano T; Ishikawa SE
Endocr J; 2021 Jan; 68(1):17-29. PubMed ID: 32863282
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
Park GH; Lee CM; Song JW; Jung MC; Kim JK; Song YR; Kim HJ; Kim SG
Korean J Intern Med; 2018 May; 33(3):561-567. PubMed ID: 28286940
[TBL] [Abstract][Full Text] [Related]
13. Long-term low-dose tolvaptan efficacy and safety in SIADH.
Bondanelli M; Aliberti L; Gagliardi I; Ambrosio MR; Zatelli MC
Endocrine; 2023 Nov; 82(2):390-398. PubMed ID: 37507553
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery.
Kleindienst A; Georgiev S; Schlaffer SM; Buchfelder M
J Endocr Soc; 2020 Jul; 4(7):bvaa068. PubMed ID: 32666012
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan.
Kim Y; Lee N; Lee KE; Gwak HS
Eur J Clin Pharmacol; 2020 May; 76(5):723-729. PubMed ID: 32055900
[TBL] [Abstract][Full Text] [Related]
17. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
[TBL] [Abstract][Full Text] [Related]
18. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study.
Burst V; Grundmann F; Kubacki T; Greenberg A; Rudolf D; Salahudeen A; Verbalis J; Grohé C
Support Care Cancer; 2017 Jul; 25(7):2275-2283. PubMed ID: 28255808
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
Dasta JF; Chiong JR; Christian R; Lin J
Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
[TBL] [Abstract][Full Text] [Related]
20. Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis.
Meena AK; Nanda PM; Sharma R; Chakrabarty B; Gulati S
Indian J Pediatr; 2024 Feb; 91(2):188-190. PubMed ID: 36757652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
